a
a
Weather:
No weather information available
HomeHealthUCB to unveil new data for RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session

UCB to unveil new data for RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session

UCB will showcase 18 abstracts, including an oral presentation, demonstrating continued commitment to advancing targeted treatments for generalized myasthenia gravis (gMG). Presentations include new post hoc analyses considering corticosteroid dose tapering during treatment with RYSTIGGO®…

No comments

Sorry, the comment form is closed at this time.

Translate »